Imperial College spin-out Photobiotics reckons it's on track towards making photodynamic therapy (PDT) more targeted, as well as addressing some of the technique's other weaknesses.
You may also be interested in...
Norway's PhotoCure is one of the few European biotech companies with a marketed product. Skin cancer photodynamic therapy Metvix PDT has already been launched in Scandinavia, and more recently by partner Galderma in Germany and the UK. Other PDT firms have struggled to educate physicians to accept a new kind of treatment-and thereby recoup the costs attached. PhotoCure is hoping that Metvix's improved efficacy and cosmetic advantages will help it create a market for PDT products.
Psimei Pharmaceuticals aims to improve the outcome of conventional radiotherapy for cancer patients by applying its Photon Activation Therapy (PAT) and Boron Neutron Capture Therapy (BNCT) technologies. The UK start-up has so far raised one million pounds since it was founded in January 2001.
For Sir Richard Sykes, chairman of GlaxoSmithKline PLC and Rector of Imperial College of Science Technology & Medicine since the beginning of 2001, strong interaction between different faculties is the key to effectively exploiting the College's intellectual assets. The interdisciplinary approach taken by the College itself-its new BioMedical building built in the heart of the campus, close to Chemistry and Engineering-and by Imperial College Innovations Ltd., the College's technology transfer company, reflects this belief. "The Rector's view is that the big technologies of the future will be founded at the interstices of the various faculties," outlines Jon Taylor, former CEO of Imperial College Innovations.